A Phase I, Multicenter, Open-label, Dose Escalation Study of Intravenous Administration of VCN-01 Oncolytic Adenovirus With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs VCN 01 (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Gastrointestinal stromal tumours; Head and neck cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors VCN Biosciences
- 16 Sep 2019 Planned End Date changed from 1 Sep 2019 to 1 Oct 2020.
- 03 Sep 2019 According to a VCN Bioscience media release, data from this trial will be presented at the annual meeting of the European Society of Medical Oncology (ESMO) in Barcelona, 27 September -1 October 2019.
- 29 Apr 2019 Planned End Date changed from 1 May 2019 to 1 Sep 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History